Phase II randomized pharmacogenetic study to evaluate the efficacy and safety of high-dose FOLFIRI schedule of irinotecan (FOLFIRI-AD) in patients with metastatic colorectal cancer according to UGT1A genotype 1.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms FOLFIRI-AD
- 07 May 2015 Biomarkers information updated
- 11 Jul 2012 Additional lead trial centres and investigators (Baiget M, Paez D) added as reported by ClinicalTrials.gov.
- 11 Jul 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health, NCT01639326).